

Rhythm appoints new Chair

Highlights

- ✓ **Gavin Fox-Smith appointed Chair of Rhythm Biosciences; and**
- ✓ **Otto Buttula retired at FY25 Annual General Meeting as Chair and Director.**

Melbourne, Australia, 5 November 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, the RHY board are pleased to announce that Gavin Fox-Smith has been appointed Chair of Rhythm Biosciences following the retirement of Otto Buttula at the FY25 AGM.

Otto's planned retirement as Chair and as a director was announced on 23 June 2025. The Board thanks Otto for his outstanding leadership, including his time as Executive Chair, and for his unwavering support as one of RHY's largest shareholders—his contributions have been pivotal to RHY's continued development and transformation to a commercial enterprise.

The Board is delighted to announce the appointment of Gavin Fox-Smith as Chair of Rhythm Biosciences, effective 5 November 2025. Gavin is an experienced company director, and the Board looks forward to his leadership in the next phase of the Company's growth.

Gavin Fox-Smith commented: "I am honoured to take on the role of Chairman at such an exciting time for Rhythm. On behalf of the Board, I extend our deepest thanks to Otto for his dedication and vision. I look forward to working with the Board and management team to continue building on the Company's strong foundation and driving ultimate value for our shareholders."

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

Directors

Gavin Fox-Smith	Non-Executive Chairman
Sue MacLeman	Non-Executive Director
David Atkins	CEO & Managing Director

www.rhythmbio.com

E investors@rhythmbio.com

The ColoSTAT[®] Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT[®] Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType[™]

geneType[™] is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.